2024 J clin oncol. 2009 27 33 : 5594-600

J clin oncol. 2009 27 33 : 5594-600

Author: vxau

August undefined, 2024

WebJ Clin Oncol. 2009 Dec 10;27 (35):6027-32. link to original article contains dosing details in manuscript PubMed NCT00418535 DEP & RT DEP & RT: D examethasone, E toposide, P … WebSep 16, 2012 · J Clin Oncol. 2011;29(33):4410–6. Article PubMed CAS Google Scholar Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, et al. Efficacy of L …

Salvage regimens with autologous transplantation for relapsed ... - PubMed

WebMay 15, 2024 · J Clin Oncol. 2004; 22 (5):785–94. [Google Scholar] 9. Mcbride WG. Thalidomide and congenital abnormalities. ... 2009; 27 (9):932–36. [Google Scholar] ... :593–600. [Google Scholar] 19. Yau T, Chan P, Wong H, et al. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced … WebNov 20, 2009 · J Clin Oncol. 2009 Nov 20;27(33):5529-37.doi: 10.1200/JCO.2008.20.6847. Epub 2009 Sep 28. Authors Bella Kaufman 1 , John R Mackey, Michael R Clemens, Poonamalle P Bapsy, Ashok Vaid, Andrew Wardley, Sergei Tjulandin, Michaela Jahn, Michaela Lehle, Andrea Feyereislova, Cédric Révil, Alison Jones Affiliation closet built ins kids

Overview of the current treatment strategy in extranodal …

WebJul 18, 2024 · JAK/STAT Pathway. The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is important for hematopoiesis and immune … WebNov 20, 2009 · DOI: 10.1200/JCO.2008.20.6847. Abstract. Purpose: TAnDEM is the first randomized phase III study to combine a hormonal agent and trastuzumab without … WebJul 29, 2024 · J Clin Oncol 2009;27:5594-600. [ Crossref ] [ PubMed ] Dong LH, Zhang LJ, Wang WJ, et al. Sequential DICE combined with l-asparaginase chemotherapy followed by … closet built-in shelves

Phase I/II Study of Concurrent Chemoradiotherapy for …

A novel prostate cancer subtyping classifier based on luminal and …

WebFeb 25, 2010 · Phase II Study of Gemcitabine Chemotherapy Alone for Locally Advanced Pancreatic Carcinoma: JCOG0506 Japanese Journal of Clinical Oncology Oxford Academic AbstractObjective. Chemoradiotherapy with 5-fluorouracil has been accepted as a standard care for locally advanced pancreatic cancer; however, it has not been s WebApr 14, 2024 · INTRODUCTION. Prostate cancer (PCa) results in more than 375,000 deaths worldwide on an annual basis and represents a clinically and biologically diverse disease process. 1-5 A substantial heterogeneity of prognosis exists even within subgroups of PCa defined by clinicopathologic features. 6, 7 As we move beyond clinicopathologic … closet butler ventilated shelvingWebNov 10, 2024 · 33. Arya S, Kim SI, Duwayri Y, et al. Frailty increases the risk of 30-day mortality, morbidity, and failure to rescue after elective abdominal aortic aneurysm repair … closet by carla moreira

"WebFeb 2, 2015 · In these reports, the dose and schedule of DCF were as follows: docetaxel (50–70 mg/m 2, Day 1), cisplatin (60–70 mg/m 2, Day 1) and fluorouracil (600–800 mg/m 2, Days 1–5) every 3–4 weeks. Although these reports showed promising efficacy, they also report severe toxicities, particularly those related to myelosuppression. " - J clin oncol. 2009 27 33 : 5594-600

J clin oncol. 2009 27 33 : 5594-600

Progression-free survival at 24 months and subsequent

WebOct 24, 2024 · In 2009, Yamaguchi et al. conducted a trial in localized nasal type using concurrent radiation therapy (50 Gy) and DeVIC chemotherapy (dexamethasone, etoposide, ifosfamide, and carboplatin). The overall response rate was 81%, and 77% of the 27 patients achieved a complete response. WebAug 31, 2009 · The Gynecologic Oncology Group (GOG) has reported on seven randomized phase III trials in this setting with only one regimen being superior to single-agent cisplatin administered intravenously at 50 mg/m 2 every 3 weeks. 6 When added to cisplatin, topotecan at 0.75 mg/m 2 on the first 3 days of a 21-day cycle prolonged the median …

Did you know?

WebJ Clin Oncol 2009;27:5594-600. DOI PubMed; 37. Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: consortium for Improving Survival of Lymphoma study. J Clin Oncol 2009;27:6027-32. DOI PubMed; 38. WebSep 20, 2010 · Purpose: Salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT) is the standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL). Salvage regimens have never been compared; their efficacy in the rituximab era is unknown. Patients and methods: Patients with CD20(+) DLBCL in …

Web2 days ago · Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Â© 2024 27 Centers of Multicenter Hematology-Oncology Programs Evaluation System (M-HOPES) First randomized controlled phase III trial of early-stage natural killer/T-cell ... WebJai N Patel Department of Cancer Pharmacology, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA Abstract: Cancer pharmacogenomics is an …

WebJournal of Clinical Oncology. 2009 Nov 20;27(33):5594-5600. doi: 10.1200/JCO.2009.23.8295 Yamaguchi, Motoko ; Tobinai, Kensei ; Oguchi, Masahiko et al. / Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma : Japan clinical oncology group study JCOG0211 . WebOct 1, 2009 · To explore a more effective treatment for localized nasal natural killer (NK)/T-cell lymphoma, we conducted a phase I/II study of concurrent chemoradiotherapy. Treatments comprised concurrent...

WebApr 12, 2024 · Journal of Clinical Oncology (JCO) is a high-impact, peer-reviewed medical journal that publishes significant clinical oncology research along with editorials, reviews, and other works that relate to the care of patients with cancer. Journal of Clinical Oncology Skip to main content Log In submission complete icon Submit envelope E-Alerts cart Cart

WebApr 14, 2024 · Christopher J. Sweeney has been a consultant for Astellas Pharma, Pfizer, CellCentric, Bayer HealthCare Pharmaceuticals, Point Biopharma, Sanofi US Services, AstraZeneca, Janssen Biotech, and Genentech. Edward M. Schaeffer has been a consultant for Pinnacle, Astellas Pharma, Pfizer Canada, and Lantheus Medical Imaging. closetbykellWebNov 3, 2016 · J Clin Oncol 27:5594-5600. © 2009 by American Society of Clinical Oncology INTRODUCTION Extranodal natural killer (NK)/T-cell lymphoma (NKTCL), nasal type,1,2 … closet by design atlantaWebSep 17, 2024 · J Clin Oncol. 2009;27:5594–600. Article CAS PubMed Central Google Scholar ... J Clin Oncol. 2015;33:2516–22. Article CAS PubMed Central Google Scholar ... closet by design barrie closet bypass barn doorsWebJ Clin Oncol 2009;27:5594-600. Kim SJ, Kim K, Kim BS, et al. Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, … closet by design birminghamWebLenvatinib. Lenvatinib is a TKI targeting VEGFR 1–3, PDGFR-α, fibroblast growth factor receptor 1–4 (FGFR 1–4), KIT and rearrangement during transfection (RET). 29 Through the inhibition of VEGFR and FGFR pathways, lenvatinib activity is characterized by a more pleiotropic effect when compared to sorafenib. 29–32 Intriguingly, the two TKIs shared … closet bypass door floor guide hardwareWebJun 25, 2013 · Extranodal, nasal-type natural-killer (NK)/T-cell lymphoma is a rare presentation of malignant lymphoma; in Noth America and Europe, however, it is most prevalent in Asia and South America. This clinical entity represents a clinically pathological and immunohistochemical heterogenous disease. closet by design houston